Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA CRC-203: Pumitamig plus chemotherapy vs bevacizumab plus chemotherapy in first-line unresectable or metastatic colorectal cancer
jRCT2031250753Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of pumitamig in colorectal adenocarcinoma (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Progression-free survival (PFS) - Phase 2, Overall survival (OS) - Phase 3 and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
pumitamig
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on jRCT2031250753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250753.